tbuckley/cabot-search huggingface dataset:
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
Authors: Andrea Dennis, Daniel J Cuthbertson, Dan Wootton, Michael Crooks, Mark Gabbay, Nicole Eichert, Sofia Mouchti, Michele Pansini, Adriana Roca-Fernandez, Helena Thomaides-Brears, Matt Kelly, Matthew Robson, Lyth Hishmeh, Emily Attree, Melissa Heightman, Rajarshi Banerjee, Amitava Banerjee
Journal: Journal of the Royal Society of Medicine (2023)

Objectives To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation. Design Prospective cohort study. Participants Individuals. Methods In individuals recovered from acute COVID-19, we assessed symptoms, health status, and multi-organ tissue characterisation and function. Setting Two non-acute healthcare settings (Oxford and London). Physiological and biochemical investigations were performed at baseline on all individuals, and those with organ impairment were reassessed. Main outcome measures Primary outcome was prevalence of single- and multi-organ impairment at 6 and 12 months post COVID-19. Results A total of 536 individuals (mean age 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post COVID-19); 331 (62%) with organ impairment or incidental findings had follow-up, with reduced symptom burden from baseline (median number of symptoms 10 and 3, at 6 and 12 months, respectively). Extreme breathlessness (38% and 30%), cognitive dysfunction (48% and 38%) and poor health-related quality of life (EQ-5D-5L &lt; 0.7; 57% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single-organ impairment. Single- and multi-organ impairment were present in 69% and 23% at baseline, persisting in 59% and 27% at follow-up, respectively. Conclusions Organ impairment persisted in 59% of 331 individuals followed up at 1 year post COVID-19, with implications for symptoms, quality of life and longer-term health, signalling the need for prevention and integrated care of long COVID. Trial Registration: ClinicalTrials.gov Identifier: NCT04369807
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
Authors: Latifa Zekri, Martina Lutz, Nisha Prakash, Timo Manz, Boris Klimovich, Stefanie Mueller, Sebastian Hoerner, Ilona Hagelstein, Monika Engel, Anna Chashchina, Martin Pfluegler, Jonas S. Heitmann, Gundram Jung, Helmut R. Salih
Journal: Molecular Therapy (2023)

T cell-based immunotherapy has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions remain rare, particularly in gastrointestinal cancers like colorectal cancer (CRC). B7-H3 is overexpressed in multiple cancer entities including CRC on both tumor cells and tumor vasculature, the latter facilitating influx of effector cells into the tumor site upon therapeutic targeting. We generated a panel of T cell-recruiting B7-H3xCD3 bispecific antibodies (bsAbs) and show that targeting a membrane-proximal B7-H3 epitope allows for a 100-fold reduction of CD3 affinity. In vitro, our lead compound CC-3 showed superior tumor cell killing, T cell activation, proliferation, and memory formation, whereas undesired cytokine release was reduced. In vivo, CC-3 mediated potent antitumor activity in three independent models using immunocompromised mice adoptively transferred with human effector cells with regard to prevention of lung metastasis and flank tumor growth as well as elimination of large established tumors. Thus, fine-tuning of both target and CD3 affinities as well as binding epitopes allowed for the generation of a B7-H3xCD3 bsAbs with promising therapeutic activity. CC-3 is presently undergoing good manufacturing practice (GMP) production to enable evaluation in a clinical "first-in-human" study in CRC. T cell-based immunotherapy has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions remain rare, particularly in gastrointestinal cancers like colorectal cancer (CRC). B7-H3 is overexpressed in multiple cancer entities including CRC on both tumor cells and tumor vasculature, the latter facilitating influx of effector cells into the tumor site upon therapeutic targeting. We generated a panel of T cell-recruiting B7-H3xCD3 bispecific antibodies (bsAbs) and show that targeting a membrane-proximal B7-H3 epitope allows for a 100-fold reduction of CD3 affinity. In vitro, our lead compound CC-3 showed superior tumor cell killing, T cell activation, proliferation, and memory formation, whereas undesired cytokine release was reduced. In vivo, CC-3 mediated potent antitumor activity in three independent models using immunocompromised mice adoptively transferred with human effector cells with regard to prevention of lung metastasis and flank tumor growth as well as elimination of large established tumors. Thus, fine-tuning of both target and CD3 affinities as well as binding epitopes allowed for the generation of a B7-H3xCD3 bsAbs with promising therapeutic activity. CC-3 is presently undergoing good manufacturing practice (GMP) production to enable evaluation in a clinical "first-in-human" study in CRC.
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Authors: Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Journal: Liver Cancer (2023)

KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported.
Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities
Authors: Tara Srinivas, Carolina Mathias, Cristina Oliveira-Mateos, Sonia Guil
Journal: Molecular Therapy (2023)

Investigation of lncRNA functions in the CNS is a rapidly expanding field that holds exciting potential for new advances in understanding brain cell physiology and improving disease diagnosis and therapy. This review summarizes important evidence regarding the roles of lncRNAs in brain cellular and molecular processes, highlighting a few lncRNAs that have been studied as biomarkers of CNS disorders involving neurodegeneration, neurodevelopment, and more. Our current understanding is that lncRNAs have a fine-tuning influence in a variety of human diseases and represent a type of molecule that can be easily targeted with high specificity. However, direct involvement of lncRNAs in brain pathologies has been shown for only a reduced number of cases. Given that CNS tissues exhibit large enrichment and diversity of ncRNAs, future research will be key to elucidating the roles of known and still unidentified lncRNAs in the CNS, expanding the potential of these noncodings to serve as diagnostic biomarkers and even targets for treatment of CNS conditions.
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden
Authors: Marta Biondi, Sarah Tettamanti, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Rocco Piazza, Samantha Donsante, Simone Bido, Vincenzo Maria Perriello, Vania Broccoli, Andrea Doni, Francesco Dazzi, Alberto Mantovani, Gianpietro Dotti, Andrea Biondi, Alice Pievani, Marta Serafini
Journal: Blood (2023)

Acute myeloid leukemia (AML) is a hematological malignancy derived from neoplastic myeloid progenitor cells characterized by abnormal clonal proliferation and differentiation. Although novel therapeutic strategies have recently been introduced, the prognosis of AML remains unsatisfactory. So far, the efficacy of chimeric antigen receptor (CAR)-T therapy in AML has been hampered by several factors including the poor accumulation of the blood-injected cells in the leukemia bone marrow (BM) niche, where chemotherapy-resistant leukemic stem cells reside. Thus, we hypothesized that overexpression of CXCR4, whose ligand CXCL12 is highly expressed by BM stromal cells within the niche, could improve T cell homing to the BM and consequently enhance their intimate contact with BM-resident AML cells facilitating disease eradication. Specifically, we engineered conventional CD33.CAR-cytokine induced killer cells (CIKs) with the wild-type CXCR4 and the variant CXCR4R334X, responsible for leukocyte sequestration in the BM of WHIM syndrome patients. Overexpression of both CXCR4wt and CXCR4mut in CD33.CAR-CIKs resulted in significant improvement of chemotaxis toward recombinant CXCL12 or BM stromal cell conditioned medium with no observed impairment of cytotoxic potential in vitro. Moreover, CXCR4-overexpressing CD33.CAR-CIKs showed enhanced in vivo BM homing, associated with a prolonged retention for the CXCR4R334X variant. However, only CD33.CAR-CIKs co-expressing CXCR4wt but not CXCR4mut exerted a more sustained in vivo antileukemic activity and extended animal survival, suggesting a non-canonical role for CXCR4 in modulating CAR-CIK functions independent of BM homing. Taken together, these data suggest that arming CAR-CIKs with CXCR4 may represent a promising strategy for increasing their therapeutic potential for AML.
Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis
Authors: Jiaru Yang, Jing Kong, Bingxue Li, Zhenhua Ji, Aihua Liu, Jingjing Chen, Meixiao Liu, Yuxin Fan, Li Peng, Jieqin Song, Xinya Wu, Li Gao, Weijiang Ma, Yan Dong, Suyi Luo, Fukai Bao
Journal: Journal of Infection (2023)
Tick-borne encephalitis: Acute clinical manifestations and severity in 581 cases from Germany, 2018–2020
Authors: Teresa M. Nygren, Antonia Pilic, Merle M. Böhmer, Christiane Wagner-Wiening, Simone-Beatrice Went, Ole Wichmann, Wiebke Hellenbrand
Journal: Journal of Infection (2023)
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow
Authors: Anita Y. Kinney, Scott T. Walters, Yong Lin, Shou-En Lu, Arreum Kim, Julianne Ani, Emily Heidt, Circe J.G. Le Compte, Denalee O'Malley, Antoinette Stroup, Lisa E. Paddock, Sherry Grumet, Tawny W. Boyce, Deborah L. Toppmeyer, Jean A. McDougall
Journal: Journal of Clinical Oncology (2023)

Cancer genetic risk assessment (CGRA) is recommended for women with ovarian cancer or high-risk breast cancer, yet fewer than 30% receive recommended genetic services, with the lowest rates among underserved populations. We hypothesized that compared with usual care (UC) and mailed targeted print (TP) education, CGRA uptake would be highest among women receiving a phone-based tailored risk counseling and navigation intervention (TCN).
Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen–radioguided Surgery. Eur Urol 2022;83:62–9
Authors: André Pontes-Silva
Journal: European Urology (2023)
Bronchial epithelial cell transcriptional responses to inhaled corticosteroids dictate severe asthmatic outcomes
Authors: Scott P. Ginebaugh, Matthias Hagner, Anuradha Ray, Serpil C. Erzurum, Suzy A.A. Comhair, Loren C. Denlinger, Nizar N. Jarjour, Mario Castro, Prescott G. Woodruff, Stephanie A. Christenson, Eugene R. Bleecker, Deborah A. Meyers, Annette T. Hastie, Wendy C. Moore, David T. Mauger, Elliot Israel, Bruce D. Levy, Sally E. Wenzel, Matthew J. Camiolo
Journal: Journal of Allergy and Clinical Immunology (2023)
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Authors: Pedro M Machado, Martin Schäfer, Satveer K Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G S Saad, Christopher E M Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F Mateus, Emily Sirotich, Enrique R Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajão Martins, Helena Santos, Jonathan Dau, Jonathan N Barker, Jonathan Hausmann, Kimme L Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M Pinheiro, Marcos David Zelaya, María de los Ángeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S Wallace, Zenas Z N Yiu, Jinoos Yazdany, Philip C Robinson, Catherine H Smith
Journal: Annals of the Rheumatic Diseases (2023)

Objectives To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. Results Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25–2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39–2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42–0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. Conclusion Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Authors: Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Benedicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindström, Johan Askling
Journal: Annals of the Rheumatic Diseases (2023)

Objective Longitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our objective was to assess and compare incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA), updating previous reports and including newer treatments including Janus Kinase inhibitors (JAKi). Methods Nationwide register-based cohort study including all patients with RA in Sweden registered as starting any b/tsDMARD 1 January 2010 through 31 December 2020, followed until 30 June 2021 (N=20 117). The incidence rates of selected outcomes, identified through national healthcare registers, were compared between individual b/tsDMARDs, adjusted for confounding by demographics, RA disease characteristics and comorbidity. Results There were marked differences in treatment discontinuations due to adverse events (rates per 1000 person-years ranged from 18 on rituximab to 57 on tofacitinib), but few significant differences were observed for the serious adverse events under study. Neither cardiovascular events nor general serious infections were more frequent on baricitinib or tofacitinib versus bDMARDs, but JAKi were associated with higher rates of hospital-treated herpes zoster (HR vs etanercept, 3.82 (95% CI 2.05 to 7.09) and 4.00 (1.59 to 10.06)). Low number of events limited some comparisons, in particular for sarilumab and tofacitinib. Conclusion Data from ARTIS supports that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.
Gut virome-colonising<i>Orthohepadnavirus</i>genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation<i>in vivo</i>
Authors: Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spanò, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara Bonini, Laurent Peyrin-Biroulet, Alberto Malesci, Vipul Jairath, Silvio Danese, Federica Ungaro
Journal: Gut (2023)

Ulcerative colitis (UC) is a chronic inflammatory disorder of unknown aetiology. Gut virome dysbiosis is fundamental in UC progression, although its role in the early phases of the disease is far from fully understood. Therefore, we sought to investigate the role of a virome-associated protein encoded by the
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis
Authors: Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q Huynh, Anne M Griffiths, Dan Turner, Karen L Madsen, Paul Moayyedi, A Hillary Steinhart, Mark S Silverberg, Colette Deslandres, Alain Bitton, David R Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru
Journal: Gut (2023)

The measure of serum proteome in the preclinical state of Crohn's disease (CD) may provide insight into biological pathways involved in CD pathogenesis. We aimed to assess associations of serum proteins with future CD onset and with other biomarkers predicting CD risk in a healthy at-risk cohort.
Spatiotemporal variation in risk of Shigella infection in childhood: a global risk mapping and prediction model using individual participant data
Authors: Hamada S Badr, Josh M Colston, Nhat-Lan H Nguyen, Yen Ting Chen, Eleanor Burnett, Syed Asad Ali, Ajit Rayamajhi, Syed M Satter, Nguyen Van Trang, Daniel Eibach, Ralf Krumkamp, Jürgen May, Ayola Akim Adegnika, Gédéon Prince Manouana, Peter Gottfried Kremsner, Roma Chilengi, Luiza Hatyoka, Amanda K Debes, Jerome Ateudjieu, Abu S G Faruque, M Jahangir Hossain, Suman Kanungo, Karen L Kotloff, Inácio Mandomando, M Imran Nisar, Richard Omore, Samba O Sow, Anita K M Zaidi, Nathalie Lambrecht, Bright Adu, Nicola Page, James A Platts-Mills, Cesar Mavacala Freitas, Tuula Pelkonen, Per Ashorn, Kenneth Maleta, Tahmeed Ahmed, Pascal Bessong, Zulfiqar A Bhutta, Carl Mason, Estomih Mduma, Maribel P Olortegui, Pablo Peñataro Yori, Aldo A M Lima, Gagandeep Kang, Jean Humphrey, Robert Ntozini, Andrew J Prendergast, Kazuhisa Okada, Warawan Wongboot, Nina Langeland, Sabrina J Moyo, James Gaensbauer, Mario Melgar, Matthew Freeman, Anna N Chard, Vonethalom Thongpaseuth, Eric Houpt, Benjamin F Zaitchik, Margaret N Kosek
Journal: The Lancet Global Health (2023)
Cost-effectiveness of low-dose aspirin for the prevention of preterm birth: a prospective study of the Global Network for Women's and Children's Health Research
Authors: Jackie K Patterson, Simon Neuwahl, Norman Goco, Janet Moore, Shivaprasad S Goudar, Richard J Derman, Matthew Hoffman, Mrityunjay Metgud, Manjunath Somannavar, Avinash Kavi, Jean Okitawutshu, Adrien Lokangaka, Antoinette Tshefu, Carl L Bose, Abigail Mwapule, Musaku Mwenechanya, Elwyn Chomba, Waldemar A Carlo, Javier Chicuy, Lester Figueroa, Nancy F Krebs, Saleem Jessani, Sarah Saleem, Robert L Goldenberg, Kunal Kurhe, Prabir Das, Archana Patel, Patricia L Hibberd, Emmah Achieng, Paul Nyongesa, Fabian Esamai, Sherri Bucher, Edward A Liechty, Brian W Bresnahan, Marion Koso-Thomas, Elizabeth M McClure
Journal: The Lancet Global Health (2023)

Premature birth is associated with an increased risk of mortality and morbidity, and strategies to prevent preterm birth are few in number and resource intensive. In 2020, the ASPIRIN trial showed the efficacy of low-dose aspirin (LDA) in nulliparous, singleton pregnancies for the prevention of preterm birth. We sought to investigate the cost-effectiveness of this therapy in low-income and middle-income countries. In this post-hoc, prospective, cost-effectiveness study, we constructed a probabilistic decision tree model to compare the benefits and costs of LDA treatment compared with standard care using primary data and published results from the ASPIRIN trial. In this analysis from a health-care sector perspective, we considered the costs and effects of LDA treatment, pregnancy outcomes, and neonatal health-care use. We did sensitivity analyses to understand the effect of the price of the LDA regimen, and the effectiveness of LDA in reducing both preterm birth and perinatal death. In model simulations, LDA was associated with 141 averted preterm births, 74 averted perinatal deaths, and 31 averted hospitalisations per 10 000 pregnancies. The reduction in hospitalisation resulted in a cost of US$248 per averted preterm birth, $471 per averted perinatal death, and $15·95 per disability-adjusted life year. LDA treatment in nulliparous, singleton pregnancies is a low-cost, effective treatment to reduce preterm birth and perinatal death. The low cost per disability-adjusted life year averted strengthens the evidence in support of prioritising the implementation of LDA in publicly funded health care in low-income and middle-income countries. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The Global Alliance for Chronic Diseases researchers’ statement on non-communicable disease research with Indigenous peoples
Authors: David P Meharg, Violet Naanyu, Boe Rambaldini, Marilyn J Clarke, Cameron Lacey, Felix Jebasingh, Patricio Lopez-Jaramillo, Gillian S Gould, Benjamin Aceves, Jennifer A Alison, Michael Chaiton, Jun Chen, Francisco Gonzalez-Salazar, Felicity Goodyear-Smith, Kylie G Gwynne, Kylie S Lee, Diana MacKay, Louise Maple-Brown, Brian L Mishara, Gustavo Nigenda, Anusha Ramani-Chander, Stephen G Sherwood, Nihal Thomas, Amanda G Thrift, Michael Anderson
Journal: The Lancet Global Health (2023)